Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.250
Open
10.250
VWAP
10.25
Vol
52.00
Mkt Cap
122.43M
Low
10.250
Amount
533.00
EV/EBITDA(TTM)
--
Total Shares
11.40M
EV
119.35M
EV/OCF(TTM)
--
P/S(TTM)
2.05
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
20.45M
+22.23%
-0.085
-94.72%
18.60M
+31.37%
-0.090
-96.12%
22.70M
+62.9%
0.020
-113.33%
Estimates Revision
The market is revising No Change the revenue expectations for LENSAR, Inc. (LNSR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.00%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-18.00%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for LENSAR Inc (LNSR.O) is -78.85, compared to its 5-year average forward P/E of -9.99. For a more detailed relative valuation and DCF analysis to assess LENSAR Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.99
Current PE
-78.85
Overvalued PE
5.27
Undervalued PE
-25.25
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
2.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
77.27
Undervalued EV/EBITDA
-73.03
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
1.66
Current PS
10.25
Overvalued PS
2.90
Undervalued PS
0.42
Financials
Annual
Quarterly
FY2025Q3
YoY :
+16.00%
15.71M
Total Revenue
FY2025Q3
YoY :
+397.27%
-6.19M
Operating Profit
FY2025Q3
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q3
YoY :
+138.46%
-0.31
EPS - Diluted
FY2025Q3
YoY :
-212.13%
-3.51M
Free Cash Flow
FY2025Q3
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q3
YoY :
+38.73%
-18.77
FCF Margin - %
FY2025Q3
YoY :
+113.17%
-23.64
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 303.64% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
723.6K
Volume
1
0-12
Months
179.3K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LNSR News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
07:07:32
Lensar Announces Q3 Earnings Per Share of 31 Cents Compared to 13 Cents Last Year
2025-08-07 (ET)
2025-08-07
07:35:36
Lensar reports Q2 EPS (15c) vs (79c) last year
2025-05-08 (ET)
2025-05-08
07:24:52
Lensar reports Q1 EPS ($2.32) vs. (19c) last year
Sign Up For More Events
Sign Up For More Events
News
5.0
08-19NewsfilterElizabeth O'Farrell Joins the Board of Directors at SpyGlass Pharma
5.0
08-19GlobenewswireElizabeth O’Farrell Joins the Board of Directors at SpyGlass Pharma
7.0
06-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
Sign Up For More News
People Also Watch
FAQ
What is LENSAR Inc (LNSR) stock price today?
The current price of LNSR is 10.25 USD — it has increased 0 % in the last trading day.
What is LENSAR Inc (LNSR)'s business?
What is the price predicton of LNSR Stock?
What is LENSAR Inc (LNSR)'s revenue for the last quarter?
What is LENSAR Inc (LNSR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for LENSAR Inc (LNSR)'s fundamentals?
How many employees does LENSAR Inc (LNSR). have?